このエントリーをはてなブックマークに追加
ID 40503
JaLCDOI
フルテキストURL
著者
Nishimori, Hisakazu Department of Hematology, Oncology, Allergy, and Respiratory Medicine, Okayama University Hospital
Takahashi, Shunji Division of Medical Oncology and Hematology, Cancer Institute Hospital
Kiura, Katsuyuki Department of Hematology, Oncology, Allergy, and Respiratory Medicine, Okayama University Hospital
Ennishi, Daisuke Department of Hematology, Oncology, Allergy, and Respiratory Medicine, Okayama University Hospital
Kobayashi, Takayuki Division of Medical Oncology and Hematology, Cancer Institute Hospital
Sano, Koji Division of Medical Oncology and Hematology, Cancer Institute Hospital
Shinozaki, Eiji Division of Medical Oncology and Hematology, Cancer Institute Hospital
Yokoyama, Masahiro Division of Medical Oncology and Hematology, Cancer Institute Hospital
Mishima, Yuko Division of Medical Oncology and Hematology, Cancer Institute Hospital
Terui, Yasuhito Division of Medical Oncology and Hematology, Cancer Institute Hospital
Chin, Keisho Division of Medical Oncology and Hematology, Cancer Institute Hospital
Mizunuma, Nobuyuki Division of Medical Oncology and Hematology, Cancer Institute Hospital
Ito, Yoshinori Division of Medical Oncology and Hematology, Cancer Institute Hospital
Nishimura, Seiichiro Division of Breast Surgery, Cancer Institute Hospital
Takeuchi, Kengo Division of Pathology, Cancer Institute of the Japanese Foundation for Cancer Research
Ishikawa, Yuichi Division of Pathology, Cancer Institute of the Japanese Foundation for Cancer Research
Oguchi, Masahiko Division of Radiology, Cancer Institute Hospital
Tanimoto, Mitsune Department of Hematology, Oncology, Allergy, and Respiratory Medicine, Okayama University Hospital
Hatake, Kiyohiko Division of Medical Oncology and Hematology, Cancer Institute Hospital
抄録
We evaluated the efficacy and toxicity of cisplatin/docetaxel (CDDP/TXT) chemotherapy and identified prognostic factors in Japanese patients with cancer of unknown primary site (CUP). Twenty-eight consecutive patients seen at a single institute were reviewed retrospectively. Sixteen patients were treated with TXT 80mg/m2, followed by CDDP 75mg/m2. The overall response rate to CDDP/TXT treatment was 62.5%, with a median survival time (MST) of 22.7 months. Common adverse reactions were myelosuppression and hyponatremia. The MST of all 28 patients with CUP was 8.3 months, and the 1-year overall survival rate was 45.6%. Univariate analysis identified 5 prognostic factors:performance status, liver involvement, bone involvement, pleural involvement, and lymph node involvement. In conclusion, CDDP/TXT chemotherapy is effective with tolerable toxicity in patients with CUP. Japanese patients with CUP might be chemosensitive and may survive longer.
キーワード
cancer of unknown primary site (CUP)
cisplatin
docetaxel
prognosis
Amo Type
Original Article
発行日
2010-10
出版物タイトル
Acta Medica Okayama
64巻
5号
出版者
Okayama University Medical School
開始ページ
285
終了ページ
291
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
English
著作権者
CopyrightⒸ 2010 by Okayama University Medical School
論文のバージョン
publisher
査読
有り
PubMed ID
Web of Sience KeyUT